@article{article_1575691, title={Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study}, journal={Turkish Journal of Clinics and Laboratory}, volume={16}, pages={123–130}, year={2025}, DOI={10.18663/tjcl.1575691}, author={Majidova, Nargiz and Öztürk, Ahmet Emin and Çolak, Rumeysa and Yalıcı, Özge and İçli, Mehmet Cihan and Köksal, Barış and Arcagök, Murat and Taşkın, Sevdenur and Caglar, Yaprak and Güren, Ali Kaan and et al.}, keywords={Bladder cancer, neoadjuvant chemotherapy, radical cystectomy, adjuvant chemotherapy, outcome analysis}, abstract={Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in <pT2N0 and 41.1% in ≥pT2, according to substaging. After neoadjuvant treatment, 30-month DFS was 85.7% and 45.9% in the pathologic complete response (CR) and non-CR group, respectively. 30-month overall survival (OS) was 69.8% in the whole group, 71.7% in neoadjuvant and 68.2% in adjuvant. This rate in patients with neoadjuvant downstaging was 81.4% and 62% in the <pT2N0 and ≥pT2 groups, respectively. At the same time, 30-month OS in the pathologic CR and non-CR group was 100% and 62.6%, respectively. Conclusion: In patients with locally advanced bladder cancer who show a pathologically complete response to neoadjuvant chemotherapy, it is important to be evaluated in a multidisciplinary consultation in order to give cisplatin- based treatment before surgery since it has a significant contribution in terms of both DFS and OS.}, number={1}, publisher={DNT Ortadoğu Yayıncılık A.Ş.}